Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Core Insights - Milestone Pharmaceuticals is preparing for the potential launch of CARDAMYST (etripamil) nasal spray for treating symptomatic paroxysmal supraventricular tachycardia (PSVT) with a PDUFA target date set for December 13, 2025 [1][6] - The company has strengthened its financial position through a successful equity offering and an amended Royalty Purchase Agreement, providing resources for a successful launch [2][5] - Etripamil is also being developed for atrial fibrillation with rapid ventricular rate (AFib-RVR), with plans for a pivotal Phase 3 program following positive Phase 2 trial results [4][9] Financial Overview - As of September 30, 2025, Milestone reported cash and cash equivalents of $82.6 million, an increase from $69.7 million at the end of 2024 [12] - The company reported a net loss of $11.9 million for the third quarter of 2025, compared to a net loss of $9.4 million in the same period of 2024 [12][18] - Research and development expenses for the third quarter of 2025 were $3.9 million, slightly down from $4.0 million in the prior year [12][18] Clinical Development - Etripamil has shown promising efficacy and safety in clinical trials, with data from over 600 patients indicating higher conversion rates for symptomatic PSVT compared to placebo [6] - The company plans to leverage data from the PSVT NDA for the supplemental NDA regulatory approval pathway for AFib-RVR [4][6] - Recent presentations at the American Heart Association (AHA) Scientific Sessions highlighted the potential of etripamil as a rapid, self-administered treatment option [6][9]